Phenotypes associated with this allele

• Allele Symbol: Mapk14⁺
• Allele Name: wild type
• Allele ID: MGI:2438221
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Mapk14^tm1.1Dvb/Mapk14^+	B6(FVB)-Mapk14^tm1.1Dvb	MGI:5500173
ht2	Mapk14^tm1Mka/Mapk14^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	MGI:3663735
cn3	Kras^tm1Bbd/Kras^+ Mapk14^tm2Nbr/Mapk14^+ Polr2a^tm1(cre/ERT2)Bbd/Polr2a^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL	MGI:3716857
cx4	Mapk14^tm1.1Dvb/Mapk14^+ Ppm1d^tm1Lad/Ppm1d^tm1Lad	involves: 129S7/SvEvBrd * C57BL/6	MGI:5500175
cx5	Mapk14^tm1.1Dvb/Mapk14^+ Ppm1d^tm1Lad/Ppm1d^tm1Lad Tg(IghMyc)22Bri/0	involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL	MGI:3710181

Genotype
MGI:5500173

ht1

• Allelic Composition: Mapk14^tm1.1Dvb/Mapk14⁺
• Genetic Background: B6(FVB)-Mapk14^tm1.1Dvb

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

decreased pancreatic beta cell proliferation ( J:151980 )

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 4-6 month old mice (11 weeks post treatment) as compared to wild-type

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 9-14 month old mice (7 weeks post treatment) as compared to wild-type

increased pancreatic beta cell proliferation ( J:151980 )

• islet cell proliferation is increased in 10-12 month old mutant mice at 3 and at 30 days post-STZ treatment as compared to wild-type

endocrine/exocrine glands

decreased pancreatic beta cell proliferation ( J:151980 )

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 4-6 month old mice (11 weeks post treatment) as compared to wild-type

• injection with the beta cell toxin streptozocin (STZ) results in lowered blood glucose levels in 9-14 month old mice (7 weeks post treatment) as compared to wild-type

increased pancreatic beta cell proliferation ( J:151980 )

• islet cell proliferation is increased in 10-12 month old mutant mice at 3 and at 30 days post-STZ treatment as compared to wild-type

homeostasis/metabolism

decreased circulating glucose level ( J:151980 )

• pancreatic islet proliferation is decreased in aged (22-24 month old) mice, but is similar to wild-type in young mice

Genotype
MGI:3663735

ht2

• Allelic Composition: Mapk14^tm1Mka/Mapk14⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J

cardiovascular system

abnormal response to cardiac infarction ( J:82448 )

• heterozygotes are viable and overtly normal, with no significant differences in heart and body weights or baseline cardiac functional parameters relative to wild-type mice

• however, heterozygotes undergo significantly attenuated ischemia-reperfusion myocardial injury relative to wild-type counterparts

decreased myocardial infarct size ( J:82448 )

• following ischemia-reperfusion, heterozygotes display a significantly reduced myocardial infarct size relative to wild-type mice (7.20.7% vs 37.12.7%, respectively)

homeostasis/metabolism

abnormal response to cardiac infarction ( J:82448 )

• heterozygotes are viable and overtly normal, with no significant differences in heart and body weights or baseline cardiac functional parameters relative to wild-type mice

• however, heterozygotes undergo significantly attenuated ischemia-reperfusion myocardial injury relative to wild-type counterparts

decreased myocardial infarct size ( J:82448 )

• following ischemia-reperfusion, heterozygotes display a significantly reduced myocardial infarct size relative to wild-type mice (7.20.7% vs 37.12.7%, respectively)

Genotype
MGI:3716857

cn3

• Allelic Composition: Kras^tm1Bbd/Kras⁺; Mapk14^tm2Nbr/Mapk14⁺; Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL

mortality/aging

premature death ( J:122397 )

• mice live up to 40 weeks

neoplasm

increased hemolymphoid system tumor incidence ( J:122397 )

• by 24 weeks, mice develop tumors in the thymus

increased lung tumor incidence ( J:122397 )

• by 24 weeks, mice develop tumors in lungs

increased lung adenoma incidence ( J:122397 )

• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals

respiratory system

increased lung tumor incidence ( J:122397 )

• by 24 weeks, mice develop tumors in lungs

increased lung adenoma incidence ( J:122397 )

• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals

Genotype
MGI:5500175

cx4

• Allelic Composition: Mapk14^tm1.1Dvb/Mapk14⁺; Ppm1d^tm1Lad/Ppm1d^tm1Lad
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

cellular

cellular phenotype ( J:151980 )

N • double mutant Ppm1d^tm1Lad Mapk14^tm1.1Dvb mice exhibit pancreatic islet proliferation similar to wild-type, correcting the phenotype observed in Ppm1d^tm1Lad mutant mice

N • double mutant Ppm1d^tm1Lad Mapk14^tm1.1Dvb mice do not exhibit impaired glucose tolerance, correcting the phenotype observed in Ppm1d^tm1Lad/ mutant mice

Genotype
MGI:3710181

cx5

• Allelic Composition: Mapk14^tm1.1Dvb/Mapk14⁺; Ppm1d^tm1Lad/Ppm1d^tm1Lad; Tg(IghMyc)22Bri/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL

mortality/aging

premature death ( J:120284 )

• the median lifespan of 130 days

neoplasm

decreased tumor incidence ( J:120284 )

• similar to mice carrying double Ppm1d^tm1Lad allele without Mapk14^tm1Dvb allele, based on increased median survival time, mice carrying single Mapk14^tm1Dvb allele were considerably more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d⁺ allele